Survodutide
Dual GLP-1/glucagon agonist researched for obesity, MASH, and metabolic liver disease.
$170.00 / unit
1
Total:$170.00
GMP Compliant≥99% PurityGlobal Shipping
Survodutide (SUR5/SUR10) is a GLP-1/glucagon receptor dual agonist being investigated for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It combines appetite suppression with increased energy expenditure.
Key Benefits
- Dual incretin/glucagon mechanism for fat loss
- Targets liver fat and metabolic liver disease
- Significant weight loss in clinical studies
- Improves insulin sensitivity
- Once-weekly dosing
Reconstitution Instructions
- Reconstitute with Bacteriostatic Water (BAC)
- Gently swirl until fully dissolved
- Refrigerate after reconstitution (2–8°C)
Dosing Guidelines
- Once-weekly subcutaneous injection
- Titrate upward per research protocol
Product Note
Investigated for both obesity and MASH (metabolic dysfunction-associated steatohepatitis).